Corpus predominant gastritis: What does it mean?

Current Opinion in Gastroenterology

Volumn 25, Issue 6, 2009, Pages 566-569

  El Zimaity, Hala ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Autoimmune; PPI long term use; Vitamin B12 deficiency

Indexed keywords

AUTOANTIBODY; GASTRIN; INTRINSIC FACTOR; PARIETAL CELL ANTIBODY; PROTON PUMP INHIBITOR;

ANTIBIOTIC THERAPY; ATROPHIC GASTRITIS; ATROPHY; AUTOIMMUNE DISEASE; CANCER RISK; CORPUS PREDOMINANT GASTRITIS; CYANOCOBALAMIN DEFICIENCY; DISEASE ASSOCIATION; ERADICATION THERAPY; GASTRIN BLOOD LEVEL; GASTRITIS; GASTROESOPHAGEAL REFLUX; GENETIC PREDISPOSITION; HELICOBACTER INFECTION; HUMAN; PEPTIC ULCER; PERNICIOUS ANEMIA; REVIEW; STOMACH ATROPHY; STOMACH CANCER;

AGE FACTORS; AUTOIMMUNE DISEASES; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PARIETAL CELLS, GASTRIC; PROTON PUMP INHIBITORS; RISK FACTORS; VITAMIN B 12 DEFICIENCY;

EID: 74549190151     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283308d41     Document Type: Review

References (58)

1. Strickland RG. The Sydney system: auto-immune gastritis. J Gastroenterol Hepatol 1991; 6:238-243.
2. Marignani M, Delle Fave G, Mecarocci S, et al. High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia: a prospective screening study. Am J Gastroenterol 1999; 94:766-772.
3. De Block CE, Van Campenhout CM, De Leeuw IH, et al. Soluble transferrin receptor level: a new marker of iron deficiency anemia, a common manifestation of gastric autoimmunity in type 1 diabetes. Diabetes Care 2000; 23: 1384-1388.
4. Davidson RJ, Atrah HI, Sewell HF. Longitudinal study of circulating gastric antibodies in pernicious anaemia. J Clin Pathol 1989; 42:1092-1095.
5. Carmel R. Ethnic and racial factors in cobalamin metabolism and its disorders. Semin Hematol 1999; 36:88-100.
6. Carmel R, Green R, Jacobsen DW, et al. Serum cobalamin, homocysteine, and methylmalonic acid concentrations in a multiethnic elderly population: ethnic and sex differences in cobalamin and metabolite abnormalities. Am J Clin Nutr 1999; 70:904-910.
7. De Aizpurua HJ, Cosgrove LJ, Ungar B, Toh BH. Autoantibodies cytotoxic to gastric parietal cells in serum of patients with pernicious anemia. N Engl J Med 1983; 309:625-629.
8. Wangel AG, Schiller KF. Diagnostic significance of antibody to intrinsic factor. Br Med J 1966; 1:1274-1276.
9. Doniach D, Roitt IM. An evaluation of gastric and thyroid auto-immunity in relation to hematologic disorders. Semin Hematol 1964; 93:313-343.
10. Munichoodappa C, Kozak GP. Diabetes mellitus and pernicious anemia. Diabetes 1970; 19:719-722.
11. Davis RE, McCann VJ, Stanton KG. Type 1 diabetes and latent pernicious anaemia. Med J Aust 1992; 156:160-162.
12. Farnam J, Jorizzo JL, Grant JA, et al. Sjogren's syndrome presenting with hypereosinophilia, lymphopenia and circulating immune complexes. Clin Exp Rheumatol 1984; 2:41-46.
13. De Block CE, De Leeuw IH, Van Gaal LF. Autoimmune gastritis in type 1 diabetes: a clinically oriented review. J Clin Endocrinol Metab 2008; 93:363-371. A very useful review.
14. Paul I, Reichard RR. Subacute combined degeneration mimicking traumatic spinal cord injury. Am J Forensic Med Pathol 2009; 30:47-48. Case report highlights dramatic risk with subclinical vitamin B12 deficiency.
15. Strickland RG, Mackay IR. A reappraisal of the nature and significance of chronic atrophic gastritis. Am J Digest Dis 1973; 18:426-440.
16. Kekki M, Samloff IM, Varis K, Ihamaki T. Serum pepsinogen I and serum gastrin in the screening of severe atrophic corpus gastritis. Scand J Gastroenterol Suppl 1991; 186:109-116.
17. Carmel R. Pepsinogens and other serum markers in pernicious anemia. Am J Clin Pathol 1988; 90:442-445.
18. Kokkola A, Sjoblom SM, Haapiainen R, et al. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective followup study. Scand J Gastroenterol 1998; 33:88-92.
19. Qvigstad G, Qvigstad T, Westre B, et al. Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. APMIS 2002; 110:132-139.
20. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004; 99:23-32.
21. Brinton LA, Gridley G, Hrubec Z, et al. Cancer risk following pernicious anaemia. Br J Cancer 1989; 59:810-813.
22. Hsing AW, Hansson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1993; 71:745-750.
23. Malaty HM, El-Kasabany A, Graham DY, et al. Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet 2002; 359:931-935.
24. Kimura K. Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach. Gastroenterology 1972; 63:584-592.
25. El-Zimaity HMT, Gutierrez O, Kim JG, et al. Geographic differences in the distribution of intestinal metaplasia in duodenal ulcer patients. Am J Gastroenterol 2001; 96:666-672.
26. Dixon MF. Helicobacter pylori and peptic ulceration: histopathological aspects. J Gastroenterol Hepatol 1991; 6:125-130.
27. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989; 96:615-625.
28. Burstein M, Monge E, Leon-Barua R, et al. Low peptic ulcer and high gastric cancer prevalence in a developing country with a high prevalence of infection by Helicobacter pylori. J Clin Gastroenterol 1991; 13:154-156.
29. Meining A, Stolte M, Hatz R, et al. Differing degree and distribution of gastritis in Helicobacter pylori-associated diseases. Virch Archiv 1997; 431:11-15.
30. Uibo R, Vorobjova T, Metskula K, et al. Association of Helicobacter pylori and gastric autoimmunity: a population-based study. FEMS Immunol Med Microbiol 1995; 11:65-68.
31. Vorobjova T, Faller G, Maaroos HI, et al. Significant increase in antigastric autoantibodies in a long-termfollow-up study of H. pylori gastritis. Virch Archiv 2000; 437:37-45.
32. Vorobjova T, Maaroos HI, Uibo R. Immune response to Helicobacter pylori and its association with the dynamics of chronic gastritis in the antrum and corpus. APMIS 2008; 116:465-476.
33. Carmel R, Aurangzeb I, Qian D. Associations of food-cobalamin malabsorption with ethnic origin, age, Helicobacter pylori infection, and serum markers of gastritis. Am J Gastroenterol 2001; 96:63-70.
34. Graham DY, Malaty HM, Evans DG, et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991; 100:1495-1501.
35. Dehesa M, Dooley CP, Cohen H, et al. High prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic Hispanics. J Clin Microbiol 1991; 29:1128-1131.
36. Cohen H, Weinstein WM, Carmel R. Heterogeneity of gastric histology and function in food cobalamin malabsorption: absence of atrophic gastritis and achlorhydria in some patients with severe malabsorption.Gut 2000; 47:638-645.
37. Appelmelk BJ, Faller G, Claeys D, et al. Bugs on trial: the case of Helicobacter pylori and autoimmunity. Immunol Today 1998; 19:296-299.
38. Amedei A, Bergman MP, Appelmelk BJ, et al. Molecular mimicry between Helicobacter pylori antigens and H+, K+: adenosine triphosphatase in human gastric autoimmunity. J Exp Med 2003; 198:1147-1156.
39. Faller G, Winter M, Steininger H, et al. Decrease of antigastric autoantibodies in Helicobacter pylori gastritis after cure of infection. Pathol Res Pract 1999; 195:243-246.
40. Andres E, Federici L, Serraj K, Kaltenbach G. Update of nutrient-deficiency anemia in elderly patients. Eur J Intern Med 2008; 19:488-493.
41. Allen LH. How common is vitamin B-12 deficiency? Am J Clin Nutr 2009; 89:693S-696S.
42. Chan JC, Liu HS, Kho BC, et al. Longitudinal study of Chinese patients with pernicious anaemia. Postgrad Med J 2008; 84:644-650. First longitudinal study evaluating pernicious anemia in China.
43. Korbet SM, Corwin HL. Pernicious anemia associated with systemic lupus erythematosus. J Rheumatol 1986; 13:193-194.
44. Imagawa S, Yoshihara M, Ito M, et al. Evaluation of gastric cancer risk using topography of histological gastritis: a large-scaled cross-sectional study. Dig Dis Sci 2008; 53:1818-1823. Study reports corpus predominant gastritis in Japan.
45. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med 1996; 156:1097-1100.
46. Heise K, Bertran E, Andia ME, Ferreccio C. Incidence and survival of stomach cancer in a high-risk population of Chile. World J Gastroenterol 2009; 15:1854-1862.
47. Yamaji Y, Watabe H, Yoshida H, et al. High-risk population for gastric cancer development based on serum pepsinogen status and lifestyle factors. Helicobacter 2009; 14:81-86.
48. Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs 2008; 68:925-947.
49. Lamberts R, Creutzfeldt W, Struber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104:1356-1370.
50. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995; 90:1401-1406.
51. Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000; 5:206-214.
52. Graham DY, Opekun AR, Yamaoka Y, et al. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther 2003; 17:193-200.
53. UngeP,GadA, GnarpeH, Olsson J. Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study. Scand J Gastroenterol Suppl 1989; 167: 49-54.
54. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118:661-669.
55. Chourasia D, Misra A, Pandey R, Ghoshal UC. Gastric atrophy and intestinal metaplasia in a patient on long-term proton pump inhibitor therapy. Trop Gastroenterol 2008; 29:172-174. Case report highlights potential peripheral neuropathy risk with long-term PPI use without eradicating H. pylori.
56. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008; 27:1110-1121. Study examines vitamin B12 deficiency with long-term acid suppression and includes recommendations for patient management.
57. Cote GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008; 10:208-214.
58. Mason JM, Raghunath AS, Hungin AP, Jackson W. Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial. Aliment Pharmacol Ther 2008; 28:1297-1303.